Moreover, deletions occurring in the C-helix part of the EGFR exon 19 that constitute about 2.5% of all exon 19 deletions were associated with the best response as partial response rate (72.7%), and the progression-free survival (PFS) of 12.0 months in a cohort of 1138 advanced NSCLC patients treated with EGFR-TKIs [50]. Here, EGFR is linked to non-small cell lung carcinoma.